TonyPGeorgeMDFRCPC

Addiction

Chief of the Addictions Division, Professor and Co-Director of the Division of Brain and Therapeutics in the Department of Psychiatry at the University of Toronto.

Join to view full profile

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. George's full profile

Already have an account?

Office
100 Stokes Street, CAMH
BGB 3288
New Haven, CT 06510
Phone+1 416-535-8501

Fax+1 416-260-4171

Education & Training

Yale-New Haven Medical CenterInternship, Transitional Year, 1992 - 1993
Dalhousie University Faculty of MedicineClass of 1992

Certifications & Licensure

CT State Medical License 1994 - 2014

Clinical Trials

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1 Start of enrollment: 2001 Sep 01
Completed
Phase 2
Usefulness of Selegiline as an Aid to Quit Smoking - 1 Start of enrollment: 2004 Jul 01
Completed
Phase 2
Nicotinic Receptor Augmentation of SSRI Antidepressants Start of enrollment: 2003 Jan 01
Completed
Phase 2
Galantamine for Cognitive Deficits in Schizophrenia Start of enrollment: 2005 Sep 01
Completed
Phase 2, Phase 3
A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder Start of enrollment: 2004 Apr 01
Completed
Phase 1, Phase 2
rTMS Effects on Smoking Cessation and Cognition in Schizophrenia Start of enrollment: 2008 Dec 01
Completed
Not Applicable
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia Start of enrollment: 2010 Mar 01
Completed
Phase 2
Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder Start of enrollment: 2009 Nov 01
Completed
Not Applicable
Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia Start of enrollment: 2011 Nov 01
Terminated
Not Applicable
Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia Start of enrollment: 2018 Jul 01
Withdrawn
Phase 2
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder Start of enrollment: 2018 Oct 01
Withdrawn
Not Applicable
Roles: Principal Investigator
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression Start of enrollment: 2017 Nov 06
Completed
Not Applicable
Roles: Principal Investigator
Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia Start of enrollment: 2017 Jun 01
Completed
Not Applicable
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

105 citations
Current pharmacological treatments for nicotine dependence
Tony P. George, Stephanie S. O'Malley
Trends in Pharmacological Sciences. 2004-01-01
32 citations
Neurobiological Determinants of Tobacco Smoking in Schizophrenia.
Aliya M. Lucatch, Darby J. E. Lowe, Rachel C. Clark, Karolina Kozak, Tony P. George
Frontiers in Psychiatry. 2018-12-06
201 citations
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind...
Caryn Lerman, Robert A. Schnoll, Larry W. Hawk, Paul M. Cinciripini, Tony P. George
The Lancet. Respiratory Medicine. 2015-02-01

Press Mentions

The Lancet Psychiatry: Novel Approach for the Treatment of Cannabis Use Disorder Shows Promise in Phase 2 TrialDecember 6th, 2018
Legal Cannabis Is Coming. Let’s Make Sure We’re Educated About the RisksMarch 14th, 2018
Battling Prescription Drug Addiction After an Injury? You Are Not AloneMay 22nd, 2017
Join now to see all

Grant Support

Translational Studies On Smoking In SchizophreniaNational Institute On Drug Abuse2004–2006
Selegiline For Smoking CessationNational Institute On Drug Abuse2004–2006
Optimizing Treatment For Schizophrenic SmokersNational Institute On Drug Abuse2001–2004
Nicotinic Receptors And COG Function In SchizophreniaNational Institute On Drug Abuse2001–2003
Pilot Study--Selegiline For Smoking CessationNational Institute On Drug Abuse1999–2002
Gabaergic &Glutamatergic Agents--Cocaine Use In Methadone MaintenanceNational Institute On Drug Abuse1999–2002